Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

linical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's pipeline of drug candidates, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delays and requirements, clinical trial design
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... MONTREAL , Nov. 21, 2014 /PRNewswire/ ... that the European Medicines Agency (EMA) has ... the company,s lead product candidate, for the ... is a rare, severely disabling genetic disease ... tissue swelling (flare-ups) and new abnormal bone ...
(Date:11/21/2014)... Nov. 20, 2014  RedRick Technologies, a provider ... reading room environment guidance, has helped the new ... reading room, which may also serve as a ... Medicine. "In line with the ... of Radiology,s Imaging 3.0 ™ initiative, the ...
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at Citi,s 2011 Global Health Care ... presentation takes place on Tuesday, March 1, 2011 at 2:00 ... will be webcast and may be accessed on the Company,s ...
... Ortho Biotech Inc. (Centocor) today received a decision from ... Washington, D.C. overturning a 2009 federal court jury verdict ... Laboratories liable for patent infringement. A panel ... Centocor anti-tumor necrosis factor (TNF) -alpha rheumatoid arthritis treatments ...
Cached Medicine Technology:Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc. 2
(Date:11/23/2014)... 23, 2014 SWAccessControl.com's high quality access ... Recently, the company has announced its new collection of ... on these high quality power suppliers. All the new ... The special offer lasts until Dec. 20, 2014. , ... them have been supporting it for a long time. ...
(Date:11/23/2014)... 2014 The FDA is Watching: , ... On-Demand Webinar**, Dec. 11, 2014 ? Any Time at ... focus on promotional activities is no longer limited to ... looking at websites, Twitter, journal articles, TV appearances, Facebook ... Dec. 11, for On-Demand access to Timothy Ayers and ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Every year ... their communities. AlignLife experience rapid growth in the Greenville, ... very unique opportunity. AlignLife of Simpsonville will ... offices for their first annual Toy Drive. These six ... they would support with this year's toy drive. With ...
(Date:11/22/2014)... black prom dress will never go out of fashion. BellasDress.com, ... new items of black prom gowns . Now all ... up to 70% off. People throughout the world can enjoy ... made with the best materials, can make wearers feel comfortable. ... company provides these beautiful outfits in a huge range of ...
(Date:11/22/2014)... 22, 2014 “Due to my knee replacement ... from Gurnee, Ill. “While using the ice grip attachment, I ... thought there needed to be a safer way to prevent ... BLOCK. , The SPIKE BLOCK offers added safety and stability ... help to reduce injuries and damage associated with traditional spiked ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... new drug targets for mucosal fungus found in most ... genetic approach to improve treatment of common infections caused by ... by researchers at Georgetown University Medical Center. , The ... Ssk1 gene could offer a new drug target against the ...
... who report receiving written and verbal instructions on the ... significantly less likely to suffer the serious gastrointestinal and ... the drug, according to new research from the University ... the October issue Journal of General Internal Medicine ...
... Breast Cancer Funding to be a National Priority, DALLAS, ... Day,the Susan G. Komen for the Cure(R) Advocacy Alliance today ... -- that features a,bipartisan collection of voters declaring "I ... us in some way, and Americans all across,the country have ...
... American National,Insurance Company (Nasdaq: ANAT ) announced a ... share) compared to net income of,$79,245,000 ($2.98 per diluted ... security investments as well as,catastrophe losses in the property ... in earnings., After tax operating earnings for the ...
... Care, Inc. (DCI),announced today that it has completed ... PANCRECARB(R) (pancrelipase), used in the treatment,of Exocrine Pancreatic ... ("FDA"). The FDA had previously granted the product ... schedule., "Digestive Care has provided vital products ...
... providing the industry,s most aggressive defense, The Doctors Company, the largest ... is rolling out litigation education retreats for member physicians who are ... ... Calif. (Vocus) October 27, 2008 -- As part of its commitment ...
Cached Medicine News:Health News:Genetic Approach Boosts Yeast Infection Treatment 2Health News:Better instructions reduce complications among patients using common blood thinner 2Health News:Better instructions reduce complications among patients using common blood thinner 3Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Unveils New 'I Vote for the Cure'(R) Web Video 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Unveils New 'I Vote for the Cure'(R) Web Video 3Health News:American National Announces Third Quarter 2008 Results 2Health News:American National Announces Third Quarter 2008 Results 3Health News:American National Announces Third Quarter 2008 Results 4Health News:Digestive Care, Inc. Announces the Complete Submission of the NDA for PANCRECARB(R) (pancrelipase) 2Health News:The Doctors Company Launches Litigation Education Retreats to Assist Physicians Involved in Medical Litigation 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: